Accepted for/Published in: JMIR Research Protocols
Date Submitted: Jun 11, 2024
Date Accepted: Feb 23, 2025
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Effectiveness of Stromal Vascular Fraction (SVF) and Platelets Rich Plasma (PRP) in patients with Osteoarthritis: Study protocol for a phase III, prospective, randomized, controlled multi-center study: (SPOST study).
ABSTRACT
Background:
Available evidence on the conservative treatment of osteoarthritis still leaves the place for questioning on the efficacy of Platelet-Rich Plasma (PRP) and on whether Stromal Vascular Fraction (SVF) offers a superior therapeutic tool.
Objective:
To assess the clinical efficacy of SVF as adjuvant therapy to PRP on functionality and tissue regeneration for osteoarthritis.
Methods:
In a multi-centric, randomized, triple-blind controlled trial, 130 individuals with osteoarthritis will be block-randomized in a 1:1 ratio. Patients will receive an initial single PRP or PRP + SVF injection, followed by one- and two-months PRP doses. The primary endpoint is the functional improvement measured with the Single Assessment Numeric Evaluation (SANE) scale at 6 months follow-up. The secondary endpoints, gathered at 3, 6, and 12 months follow-up will include clinical outcomes: Low Extremity Functional Scale (LEFS) and Quick Disabilities of the Arm, Shoulder and Hand (quick-DASH) score, Pain Visual Analogue Scale (VAS) during maximal physical activity, SANE, the Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) (in knee osteoarthritis cases), return to work and to sports in days; and Magnetic Resonance Imaging (MRI) AMADEUS score at 6 months and at 12 months.
Results:
Participants recruitment and data collection is expected to begin in August 2024. Final end-points will be gathered in august 2027.
Conclusions:
The study results will provide insight into the clinical efficacy of SVF as adjuvant therapy to PRP on functionality and tissue regeneration in osteoarthritis. This trial is registered on ClinicalTrials.gov (NCT05660824) and SNCTP Clinical Trial: This trial is registered on ClinicalTrials.gov (NCT05660824) and SNCTP.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.